FDA Approves Adapalene Cream for Acne Vulgaris
E. Fougera & Co has received first generic approval from the FDA for Adapalene Cream 0.1% (Rx) for the treatment of acne vulgaris. Fougera’s Adapalene Cream 0.1% is rated AB, generically equivalent to Differin® by Galderma Pharmaceuticals. According to industry data, U.S. sales of the brand named product in 2009 exceeded $55 million. This approval also marks the fourth product approval that the FDA has granted to Fougera this year.
-
FDA approves New Acne Treatment
FDA approves long acting facial filler
FDA-approved wrinkle treatment hits US market
FDA gives nod to Solta Medical for aesthetic laser device
FDA approves a drug that reverses effects of local anesthesia
